Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

35 results about "Cell hypoxia" patented technology

Hypoxia is caused by any circumstance that interferes with oxygen access, including blunt force trauma, fluid loss, and tissue damage from prolonged applied pressure. Illnesses impeding normal blood flow or reducing oxygen intake also contribute to cell hypoxia.

Hypoxia response polymer nanoparticle and application thereof

The invention relates to a hypoxia response polymer nanoparticle and application thereof. The method comprises the following steps: firstly crosslinking 4,4-diaminoazobenzene and terephthalaldehyde taken as monomers, so as to form a conjugated polymer link, loading a photosensitizer and chemotherapy drugs through noncovalent interaction, and then forming the hypoxia response polymer nanoparticle through a nanoprecipitation method. The hypoxia response polymer nanoparticle can successfully carry the photosensitizer and the chemotherapy drugs to tumor cells, and produce active oxygen during illumination, so as to realize tumor killing. Azo bonds contained in the nanoparticle can be degraded under the action of reductase in cells, and chemotherapy drug release is realized. In addition, cell hypoxia caused during a photodynamic therapy process can further improve drug release, and the hypoxia response polymer nanoparticle can properly realize excellent tumor therapy effect through combination therapy effect of photodynamic therapy and chemical therapy.
Owner:MENGCHAO HEPATOBILIARY HOSPITAL OF FUJIAN MEDICAL UNIV

Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen

InactiveUS20090124584A1Good for healthReducing and improving and preventing incidenceBiocideOrganic active ingredientsPhysiologyVaginal tissue
Methods and formulations for the regeneration of vaginal tissue and vaginal cell health resulting from vaginal cell hypoxia in a human female. A pharmaceutical composition for topical non-systemic administration is formulated containing a hormonal agent administered to the vagina, vulvar area of the individual undergoing treatment.
Owner:LYLE DEV

Probe capable of realizing two-photon fluorescence detection of nitroreductase (NTR) and preparation method thereof

The invention relates to preparation of a probe capable of realizing two-photon fluorescence detection of nitroreductase (NTR) as shown in the figure (I) and belongs to the field of organic fluorescent probes. The structural formula of the probe capable of realizing two-photon fluorescence detection of the NTR is as shown in the description. The fluorescent probe provided by the invention can accurately detect the content of the NTR in cells and avoid the interference of other reducing agents in cells. In addition, the probe has the characteristics of better chemical stability, biological compatibility and selectively and the like. A laser confocal imaging experiment shows that the probe has better cell permeability, has no toxic and side effects on cells and organisms, can realize detection of content of cell level NTR and indicate the cell hypoxia condition, and can be further applied to research of precancerous detection.
Owner:NANJING TECH UNIV

Pressure control type cell hypoxia culture box

The invention discloses a pressure control type cell hypoxia culture box, and belongs to the technical field of cell culture devices. The pressure control type cell hypoxia culture box comprises a housing, wherein a gas cylinder is fixedly mounted at the left side of the top of the housing through a bolt; a pressure-reduced solenoid valve is connected to the rear sidewall of the gas cylinder through a pipeline; a flow meter is connected to the right end of the pressure-reduced solenoid valve through a pipeline; a carbon dioxide concentration solenoid valve is connected to the right end of theflow meter through a pipeline; and the front sidewall of the carbon dioxide concentration solenoid valve is connected to the top of the housing in an inserting manner through a pipeline. The pressurecontrol type cell hypoxia culture box is reasonable in design and high in practicability; electric elements such as the pressure-reduced solenoid valve, the carbon dioxide concentration solenoid valveand the like are controlled by operating a display screen; the cell growing states under different attitude environments are simulated in a negative pressure box; the comparative analysis of scientific research data is facilitated based on cell culture experiments in a negative pressure room and a normal pressure room.
Owner:兰州军区兰州总医院

Antitumor polypeptide and application thereof

The invention relates to antitumor polypeptide and application thereof. A cellular hypoxia reaction can induce expression of hypoxia-inducible factor-1alpha and initiate malignant tumors. According to identification of a hypoxia-inducible factor-1alpha protein sequence, a series of segments exist in an interval from the 10th position Lys to the 101st position Glu and an interval from the 717th position Gln to the 722nd position Met, but the segments or the polypeptide can inhibit growth and survival of cancer cells.
Owner:何明忠

Nanoprobe for detecting hypoxic cells and preparation method and uses of nanoprobe

ActiveCN112121182AAccurately reflect the degree of hypoxiaReflects the degree of hypoxiaPowder deliveryAmino preparation from aminesIntracellularNanoprobe
The present invention provides a nanoprobe for detecting hypoxic cells and a preparation method and uses of the nanoprobe. The nanoprobe is formed by self-assembly of fluorescent molecules; the fluorescent molecules are formed by condensing and oxidizing bis (4 (diethylamino) phenyl) ketone; the nanoprobe can realize fluorescence imaging of a hypoxia degree of cells by detecting the content of CYP450 enzyme in the cells; in a hypoxia environment, the nanoprobe is converted into the fluorescent molecules with strong proton adsorption capacity, so that deep penetration of tumors is realized; andthe nanoprobe has advantages of a simple synthesis method, strong water solubility, low toxicity, strong anti-interference capability, high sensitivity and strong deep penetration capability of tumors.
Owner:CHINA PHARM UNIV

Composite preparations for curing schemic brain damage

The invention relates to a compound preparation for treating the ischemic brain damage; wherein, the active component comprises prostaglandin E1 the lithium salt; the prostaglandin E1 and the lithium salt can be mixed into the intravenous injection or infusion mixture, and the prostaglandin E1 also can be made into the intravenous injection or infusion agent, meanwhile the lithium salt can be made into the subcutaneous injection. The invention has the advantages of enabling to be used on the people needing treatment or the experiment animal, inducing the formation of the heat shock protein, protects the neuron, increasingg the resistance of the cell hypoxia, and resisting the ischemic brain damage function through the synergistic interaction of the prostaglandin E1 and the lithium salt compound preparation. The invention also has an advantage that: the application dosage of two medicines in the prostaglandin E1 and the lithium salt compound preparation are both lower than the convention dosage of the two medicine in the clinic, so as to reduce the adverse reaction and improve the curative effect. The invention provides a new compound preparation for the ischemic cerebral apoplexy.
Owner:SUZHOU UNIV

Compounds, compositions and use for anticancer therapy

Cell plasma membrane impermeable compounds and compositions thereof used for anticancer treatment are provided. The compounds contain functional groups capable of blocking and / or inhibiting trans-plasma membrane electron transport (tPMET), cell surface respiration and uncoupling cell surface oxidative-phosphorylation. The compositions comprise at least one of the cell plasma membrane impermeable compounds in combination with compounds of multi-function inhibitor capable of inhibiting cancer cell hypoxia responses.
Owner:天津药和生物医药科技有限公司

Lentiviral vector of fusion green fluorescent protein with over expression of RAB7A and EGFP genes, building method and application thereof

The invention discloses a lentiviral vector of fusion green fluorescent protein with over expression of RAB7A and EGFP genes, a building method and application thereof. The vector takes a lentiviral vector LV11 as a skeleton vector, wherein an EGFP gene segments and RAB7A gene segments are inserted behind a CMV promoter of the vector LV11 in a direction from 5' to 3'. By virtue of the lentiviral vector of fusion green fluorescent protein with over expression of RAB7A and EGFP genes, the problem that over-expression vector is effective and intuitive in the study of RAB7A genes can be solved. The vector takes CMV as the promoter, so that the high-efficiency expression of eukaryotic gene can be ensured; EGFP is used as a marker, the autophagy and endocytosis degree of cells and the effect of RAB7A genes in cell hypoxia process can be judged by intuitively observing the intensity of the expressed fluorescence; a good tool is provided for studying the functions of the RAB7A genes; the basis is provided for the subsequent correlation studies of RAB7A.
Owner:SOUTHEAST UNIV

Method for establishing hypoxia injury cell model

InactiveCN109266598AReduce modeling costsSensitive to hypoxic stressCulture processBiologyBiomedical technology
The invention discloses a method for establishing a hypoxia injury cell model in the field of biomedical technology. The method comprises the following steps: S1, cell culture; 2, cell plate; S3, medium replacement; S4, cell hypoxia culture: covering a layer of permeable membrane on the culture container and culturing in a modular culture chamber containing a certain gas component; S5, cell detection. The hypoxia injury cell model established by this method does not require the participation of experimental animals, and the modeling cost is low. It is more sensitive to hypoxia stress reaction,and can be used to explore hypoxia injury at the molecular biological level. It can provide conditions for the simulation of hypoxia experiment and the screening and verification of anti-hypoxia drugs.
Owner:兰州军区兰州总医院

Medicine and composition for treating cerebral ischemic diseases

The invention belongs to the field of traditional Chinese medicines, and in particular relates to a novel application of genipin-1-[beta]-D-gentiobioside and a composition thereof. The genipin-1-[beta]-D-gentiobioside and the composition thereof can take a significant effect on treating a model rat with cerebral ischemia-reperfusion injury, obviously reduce behavioral scores of the model rat, significantly diminish the area of a brain slice infarction area of the model rat and reduce TNF-[alpha] and 1L-6 contents in serum of the model rat; an obvious therapeutic effect can be taken on a Bend.3 cell ischemic injury model which is cultured in vitro, the survival rate of injured cells can be significantly improved and a cell death-protection rate is positively related to a drug concentration; and the contents of tumor necrosis factors (TNF-[alpha]) and interleukin 6 (1L-6) in supernatant liquid of a Bend.3 cell hypoxia / reoxygenation model which is cultured in vitro can be obviously reduced. Moreover, based upon an acute toxicity test in mice and a long-term toxicity in rats, it indicates that the genipin-1-[beta]-D-gentiobioside and the composition thereof are free from toxic and side reactions.
Owner:樊向德 +1

chromatin peptide for blocking human HIF-1 alpha gene and regulating network downstream related gene

Disclosed is a category of chromatin peptide medicinal molecules capable of blocking human cell anoxybiotic reaction channels, the molecules are DNA compatible structure domain sequences of the related transcription factors or their bionic molecules or derivatives containing 5-100 amino acid residues, they can be specifically bond to HIF-1 alpha self-promotors or transcription factor driven over 40 downstream gene promotors expressed thereby, the molecules can close the molecular channels for cell anoxybiotic reactions including cell sugar glycolysis reaction and / or immunological inflammation reaction and / or vessel generation reaction, thus closing the non-controlled propagation of late stage cancer cells or chronic inflammation cells under anoxybiotic conditions.
Owner:王成球 +3

Built-in cell hypoxia culture box

The invention relates to a built-in cell hypoxia culture box, and belongs to the technical field of medical experiment tools. An air inlet, an air outlet, and openings of an oxygen sensor and a carbondioxide sensor face the interior of the box; a controller is connected with a box body, a nitrogen steel cylinder and a carbon dioxide steel cylinder separately through pipelines and wires; the controller is provided with an air inlet end and an air outlet end; an alternating-current power supply is connected to the controller; a middle transition part is arranged between the controller and the box body; the air inlet end is provided with a filter, and the filter is connected with an air pump; the air inlet end, the nitrogen steel cylinder and the carbon dioxide steel cylinder are all provided with electromagnetic valves; three corresponding circulation time relays are arranged between the three electromagnetic valves and the controller respectively. The built-in cell hypoxia culture boxis convenient to operate and high in flexibility and stability, the oxygen concentration can be precisely controlled, there is no difference in the physiological state of cells, and the experiment effect is excellent; during operation, the complete oxygen-free state can be reached; in the experiment process, variables can be rigidly controlled, and the experiment result has high accuracy.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Salidroside derivative and preparation method and application thereof

PendingCN111303222AImprove poor fat solubilityOvercoming low bioavailabilityNervous disorderSugar derivativesSalidrosideInducer Cells
The invention relates to a salidroside derivative and a preparation method and application thereof, and particularly provides a compound shown in a formula I, or salt thereof, or a stereoisomer thereof, or a crystal form thereof. The salidroside derivative shown in the formula I solves the problem of poor lipid solubility of salidroside, and can overcome the defects of low bioavailability and fastmetabolism of the salidroside in clinical application; and meanwhile, the salidroside derivative can effectively resist CoCl 2-induced PC12 cell apoptosis, has an excellent neuroprotective effect ona CoCl 2-induced PC12 cell hypoxia injury model, can be used for preparing drugs for preventing and / or treating various nervous system diseases (including parkinson disease, alzheimer disease, cerebral apoplexy and the like) related to cell hypoxia injury, and has broad application prospects.
Owner:FUJIAN UNIV OF TRADITIONAL CHINESE MEDICINE

Bio-optical composite material, preparation method and application thereof

The invention belongs to the technical field of composite materials, and particularly discloses a bio-optical composite material, a preparation method and an application thereof. The bio-optical composite material comprises the following raw materials in parts by weight: 0.5-3 parts of mica, 0.5-2 parts of mirabilite, 0.5-3 parts of haematite, 0.5-1 part of gypsum, 0.5-1 part of magnetite, 0.5-3 parts of cinnabar, 0.5-2 parts of tourmaline, 0.5-3 parts of alum and 0.5-2 parts of medical stone. The raw material fine powder of the bio-optical composite material is evenly mixed in a high-speed mixer, and is irradiated for 12-24 hours by a laser with 457-600nm frequency band and a continuous output power of 400mW. The composite material can convert infrared waves emitted by human bodies to generate short-wave biological waves, can promote cell metabolism, improve cell pathology and improve cell physiology, has the functions of quickly relieving pain, repairing cell damage, dispelling glandhyperplasia, improving cell hypoxia, enhancing muscle fiber strength, strengthening physiological state of human organs and the like, can be used for medical treatment and human body rehabilitation health care, such as preparing multiple medical patches, eyeglass frames and other human body contact articles for daily use.
Owner:上海华芝隆科技有限公司

NTR-1 response type fluorescent probe based on benzoindole as well as preparation method and application thereof

The invention discloses an NTR-1 response type fluorescent probe based on benzoindole as well as a preparation method and application of the NTR-1 response type fluorescent probe. The structure of the NTR-1 response type fluorescent probe is as defined in the specification. The method comprises the following steps: subjecting p-hydroxybenzaldehyde to reacting with p-nitrobenzyl bromide to synthesize a stable intermediate NFP-1-M connected through ether bonds, and condensing 1-ethyl-2-methylbenzo[cd]indole-1-chloride with the intermediate NFP-1-M to generate the probe NFP-1. The probe can be used for measuring the hypoxia degree of a cell, and is beneficial to early diagnosis of tumors and the like.
Owner:SOUTHEAST UNIV

RCAN1.4 promoter fragment for cell hypoxia and HIF1alpha protein activity indicator and application of RCAN1.4 promoter fragment

The invention discloses an RCAN1.4 promoter fragment for detecting a cell hypoxia state and HIF1alpha protein activity and application of the RCAN1.4 promoter fragment, and relates to the technical field of gene engineering. According to the invention, a dual-luciferase reporter gene detection system is adopted, an RCAN1.4-315-15 promoter fragment is inserted into a blank vector pGL3-basic with a firefly luciferase reporter gene, a recombinant plasmid RCAN1.4-315-15-LUC for expressing firefly luciferase is constructed, the activation condition of the RCAN1.4-315-15-LUC promoter fragment is judged by detecting the activity of the RCAN1.4-315-15-LUC luciferase, and the activity of the RCAN1.4-315-15-LUC promoter fragment is judged by detecting the activity of the firefly luciferase reporter gene. Further, the hypoxia state of the cells and the activity of the HIF1alpha protein are judged. The RCAN1.4-315-15 promoter fragment provided by the invention can be activated by the HIF1 alpha protein, has high sensitivity to the HIF1 alpha protein, and can be used as a cell hypoxia and HIF1 alpha protein activity indicator.
Owner:SHANDONG UNIV QILU HOSPITAL

Low-temperature preservation method of multifunctional 3D recombinant skin model

The invention discloses a low-temperature preservation method of a multifunctional 3D recombinant skin model. According to the invention, cytochalasin B is applied to solid preservation of a skin model for the first time, a three-step method is adopted for treatment, and the treatment method can maintain the cell activity of the model in a transportation process and reduce cell hypoxic injury, sothat the test accuracy and the cell activity of the 3D heavy skin group model are guaranteed, and the preservation time is prolonged to a great extent.
Owner:JINAN PANSHENG BIOTECH

RCAN1.1 promoter fragment for cell hypoxia and HIF1alpha protein activity indicator and application thereof

The invention discloses an RCAN1.1 promoter fragment for a cell hypoxia and HIF1alpha protein activity indicator and application thereof, and relates to the technical field of genetic engineering. According to the invention, dual-luciferase reporter gene detection system is adopted, an RCAN1.1-1030-302 promoter fragment is inserted into a blank vector pGL3-basic with a firefly luciferase reporter gene, a recombinant plasmid RCAN1.1-1030-302-LUC for expressing the firefly luciferase is constructed, the activation condition of the RCAN1.1-1030-302-LUC promoter fragment is judged by detecting the luciferase activity of the recombinant plasmid RCAN1.1-1030-302-LUC, further, the hypoxia state of the cells and the activity of the HIF1alpha protein are judged. The RCAN1.1-1030-302 promoter fragment provided by the invention can be activated by the HIF1alpha protein, has high sensitivity to the HIF1alpha protein, and can be used as a cell hypoxia and HIF1alpha protein activity indicator.
Owner:SHANDONG UNIV QILU HOSPITAL

A cryopreservation method for a multifunctional 3D reconstructed skin model

The invention discloses a low-temperature preservation method of a multifunctional 3D recombined skin model. The invention applies cytochalasin B to the solid preservation of the skin model for the first time, and adopts a three-step method for processing. The treatment method can maintain the model during transportation The cell activity in the skin can reduce the hypoxic damage of the cells, so as to ensure the accuracy of the 3D re-skin group model test and the vitality of the cells, and greatly extend the storage time.
Owner:JINAN PANSHENG BIOTECH

Fluorescent molecular probe for near-infrared photodynamic linkage detection of nitroreductase and hydrogen peroxide as well as preparation method and application of fluorescent molecular probe

The invention discloses a fluorescent molecular probe for near-infrared photodynamic linkage detection of nitroreductase and hydrogen peroxide as well as a preparation method and application of the fluorescent molecular probe. The structural formula of the fluorescent molecular probe is shown in the specification. The near-infrared fluorescent molecular probe (CNH) provided by the invention can realize visual monitoring on a cell hypoxia environment and a reoxidation process thereof, and the specific process is as follows (referring to an attached drawing 2 in the specification): under the action of a hypoxia marker nitroreductase, firstly, fluorescence is triggered from a closed state; the fluorescence is gradually enhanced along with the aggravation of the hypoxia degree; when reoxidation occurs, a fluorescence product triggered by nitroreductase (NTR) can react with H2O2 generated by reoxidation, so that fluorescence enhancement is caused in another fluorescence channel, and an enhanced ratio signal is generated to reveal the hypoxia reoxidation phenomenon in a life system.
Owner:伊明泰(山东)生物科技有限公司

Application of scirpenin C in preparation of medicine for treating cerebral arterial thrombosis

The invention provides application of scirpenin C in preparation of a medicine for treating cerebral arterial thrombosis. The scirpenin C is co-cultured with hydrogen peroxide damaged BV2 cells and hypoxia-glucose damaged BV2 cells respectively, and results show that the scirpenin C can increase the survival rate of the hydrogen peroxide damaged BV2 cells and the hypoxia-glucose damaged BV2 cells. The anti-cerebral arterial thrombosis performance of the scirpenin C is evaluated by intervening middle cerebral artery occlusion reperfusion model rats with the scirpenin C, and experimental results show that the scirpenin C can inhibit neurological function damage, reduce the cerebral infarction area caused by cerebral arterial thrombosis, reduce the cerebral dampness, significantly relieve cerebral edema and repair the blood brain barrier. The scirpenin C can also obviously reduce cell necrosis, maintain the normal state of cells, reduce the content of LDH, MDA, TNF-alpha and IL-1 beta in serum of the cerebral arterial thrombosis rats and increase the content of SOD.
Owner:GUANGDONG PHARMA UNIV

Application of compound as inhibitor of targeted phosphoglycerate kinase PGK1

The invention relates to the technical field of research and development of medicines, in particular to application of a compound serving as an inhibitor of targeted phosphoglycerate kinase PGK1. The compound has a structure as shown in a formula I; wherein R1 is selected from a structure as shown in a formula II or a formula III; r < 2 >, R < 3 >, R < 4 > and R < 7 > are independently selected from hydrogen or C1-C30 alkyl groups; r5 is selected from the group consisting of substituted or unsubstituted C6-C30 aryl groups; and R6 is selected from hydrogen, C1-C30 alkyl or halogen. Biological experiment verification is carried out on the compound with the structure as shown in the formula I, and it is found that the compound has the anti-oxidative stress effect through a fruit fly model induced by PQ toxin; an enzyme activity experiment shows that the compound can activate PGK1 in a certain range; a cell hypoxia ischemia model finds that the compound has a neuroprotective effect; through flow and western blot experiments, it is found that the compound has the effects of resisting inflammation and inhibiting cell apoptosis.
Owner:SHENZHEN READLINE BIOTECH CO LTD

Bioreactor for improving antigen yield

The invention discloses a bioreactor for improving antigen yield. The bioreactor structurally comprises a reaction tank, a clamping plate, vent holes, an additive pipeline, a motor and an object placing pipe, the surface of the reaction tank is connected with the clamping plate in a welded mode, the clamping plate is in clearance fit with the object placing pipe at the top, the right side of the object placing pipe is in clearance fit with the additive pipeline, and the additive pipeline is connected with a flange at the upper end of the reaction tank. The top of the reaction tank is integrally and movably matched with the motor, the surface of the reaction tank is fixedly connected with the vent holes in an embedded mode, the reaction tank comprises a stirring ring, an oxygen conveying rotating rod, a working cavity, a liquid discharging pipe and an auxiliary rotating frame, and the stirring ring is connected with the surface of the oxygen conveying rotating rod in an embedded mode. Oxygen is supplemented in time while the stirring strip body stirs the interior of the tank, the situation that oxygen floats upwards in the stirring process to cause hypoxia of cells is avoided, the oxygen content is conveyed into the tank in the stirring process under the cooperation of the oxygen dispersing ball, and it is guaranteed that the problems that the oxygen content is too low and the activity of the cells is reduced are solved; on the contrary, the cell activity is improved, and the antigen yield is improved.
Owner:李良生

Method for researching influence of targeted silence STAT3 on hypoxia induction of human brain glioma U251 cells and application of targeted silence STAT3

The invention discloses a method for researching the influence of targeted silence STAT3 on hypoxia induction of human brain glioma U251 cells and application of the targeted silence STAT3. The methodis characterized by constructing ShRNA of a targeted STAT3 gene to transfect a U251 cell, observing the infection efficiency with a microscope, and carrying out real-time fluorescent quantitative PCRand Western blotting to detect the silencing efficiency of STAT3; detecting the influence of STAT3 gene silencing on angiogenesis mimicry formation and invasion ability of the U251 cell induced by cell hypoxia by virtue of in-vitro three-dimensional culture and Transwell cell invasion experiments; and detecting the expression level of the VM / invasion related gene / protein through real-time fluorescent quantitative PCR and Western blotting. The ShRNA lentiviral plasmids of the targeted STAT3 gene are successfully constructed, and the U251 cell is efficiently transfected.
Owner:NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products